Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Theodore Workman

Interventional Pain Medicine Redding, CA Medical Doctor

NPI 1316970031 CMS profile 856135

2111 Airpark Dr, Redding, CA 96001

Open in the dashboard

General payments

$13,017

292 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Theodore Workman of Redding, CA is reported in the CMS Open Payments database as having received $13,017 across 292 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,204 36
2024 General $3,552 57
2023 General $349 28
2022 General $2,591 49
2021 General $2,543 27
2020 General $1,263 47
2019 General $1,514 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodore Workman
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Theodore Workman were reported at $1,204. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Theodore Workman Interventional Pain Medicine median Middle half National median
2019 $1,514 $684 $216–$2,079 $163
2020 $1,263 $382 $122–$1,109 $114
2021 $2,543 $552 $167–$1,554 $132
2022 $2,591 $605 $187–$1,924 $149
2023 $349 $671 $195–$1,915 $160
2024 $3,552 $684 $206–$1,837 $164
2025 $1,204 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,139 153 payments
  2. Spinal Simplicity, LLC $2,059 7 payments
  3. Curonix LLC $1,465 12 payments
  4. Abbott Laboratories $1,316 40 payments
  5. Vertos Medical, Inc. $1,268 7 payments
  6. SPR Therapeutics, Inc $896 7 payments
  7. Nevro Corp. $889 33 payments
  8. TerSera Therapeutics LLC $177 3 payments
  9. Painteq LLC $148 2 payments
  10. Relievant Medsystems, Inc. $128 3 payments
  11. Other $532 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,495 280 payments
  2. Travel and Lodging $3,067 8 payments
  3. Education $1,456 4 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $2,059 7 payments
  2. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $1,465 12 payments
  3. mild Device Kit $1,268 7 payments
  4. Neuromodulation Dspsbls and Accs $917 28 payments
  5. SPRINT PNS System $896 7 payments
  6. General - Pain Management $753 25 payments
  7. Senza Spinal Cord Stimulation System $640 19 payments
  8. SPECTRA WAVEWRITER $603 26 payments
  9. WaveWriter Alpha Prime 16 $336 12 payments
  10. Intracept $307 5 payments
  11. Other $3,076 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

304

Median for Pain Management: 951

Drug cost

$1,315

Median for Pain Management: $26,034

Branded share of claims

46.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 97 $593
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 45 $204
Oxycodone Hcl Generic 55 $183
Hydromorphone Hcl Generic 34 $150
Mupirocin Generic 18 $115
Tramadol Hcl Generic 55 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$750,422

Of which drugs: $12,027

Medicare patients

724

Average age 73

Services billed

16,553

458 women, 266 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Depression 30%
Chronic kidney disease 24%
Ischemic heart disease 22%
COPD 21%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 200 598 $2,318
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 412 2,842 $2,192
Injection, fentanyl citrate, 0.1 mg J3010 Office 398 759 $551
Injection, hydromorphone, up to 4 mg J1170 Office 14 102 $276
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 338 2,939 $263
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 362 1,956 $207
Injection, ketorolac tromethamine, per 15 mg J1885 Office 156 233 $122
Injection, midazolam hydrochloride, per 1 mg J2250 Office 271 615 $65
Injection, propofol, 10 mg J2704 Office 322 584 $50
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 19 74 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
  • TerSera Therapeutics LLC $177
$177 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

292 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record